Holen Sie sich die Stockscreener-App
34.10
0.41%
0.14
Handel nachbörslich:
34.47
0.37
+1.09%
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - Sahm
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Guggenheim raises Amylyx stock price target on financing, trial data - Investing.com
Broadcom Stock Leads 3 AI Infrastructure Picks With Strong Growth Potential - Sahm
Rocket Lab Stock Leads 3 High Growth Picks With Fresh Earnings Upside - Sahm
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx Pharmaceuticals (AMLX) CEO granted 60K shares - Stock Titan
Amylyx prices $500M stock offering at $35.50 per share - Investing.com
Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock - TradingView
Guggenheim raises Amylyx stock price target on trial results By Investing.com - Investing.com Australia
Amylyx (AMLX) Q2 2026 Earnings Call Transcript - AOL.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win - The Globe and Mail
AMYLYX PHARMACEUTICALS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $40 FROM $28 - Bitget
Amylyx successful phase 3 trials for blood sugar drug - EMJ
AMYLYX PHARMACEUTICALS, INC. : MIZUHO RAISES TARGET PRICE TO $42 FROM $30 - Bitget
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Guggenheim Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $55.00 - MarketBeat
A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55 - Moomoo
Guggenheim raises Amylyx stock price target on trial results - Investing.com
Amylyx Stock Sinks As Big Share Sale Spooks Wall Street - TipRanks
Robert W. Baird Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial - Yahoo
Mizuho Adjusts PT on Amylyx Pharmaceuticals to $42 From $30, Maintains Outperform Rating - Moomoo
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Wolfe Research - MarketBeat
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise - Yahoo Finance
Jason Gerberry Boosts Amylyx Price Target to $39 on Strong LUCIDITY Phase 3 Avexitide Data and $1.8B Peak Sales Outlook - TipRanks
Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Sahm
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level - sahmcapital.com
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial - KWSN
Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win - AllSci
Amylyx Pharmaceuticals (AMLX) Is Up 48.6% After Positive Phase 3 Avexitide Data And $350M Equity RaiseHas The Bull Case Changed? - simplywall.st
Amylyx Just Printed a Phase 3 Win Wall Street Wasn't Pricing - Money Morning
Key facts: Amylyx (AMLX) Files $350M Offering; Target Raised to $55 - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Amylyx Avexitide Meets Primary Endpoint in Phase 3 Post-Bariatric Hypoglycemia Trial - The Clinical Trial Vanguard
AMYLYX PHARMACEUTICALS, INC. : BAIRD RAISES TARGET PRICE TO $52 FROM $28 - Bitget
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock - BioSpace
Under the Radar: Amylyx Stock Surges On Positive Trial Results -- WSJ - moomoo.com
Amylyx Announces Positive Phase 3 Data for Avexitide, Shares Surge - NAI500
AMLX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action - TMX Newsfile
Amylyx Pharmaceuticals, Inc. stock Analysis: August 2026 Surge & Outlook - The Cryptonomist
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? - TradingView
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' R - Benzinga
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today - TradingView
Why Amylyx Pharmaceuticals Stock Skyrocketed Today - The Motley Fool
Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization - Yahoo Finance
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):